Research Topics
Species | Monika EngelhardtSummaryAffiliation: University of Freiburg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt
Hematology and Oncology Department, University of Freiburg Medical Center, Freiburg, Germany
Leuk Lymphoma 51:1424-43. 2010..This report reviews recent clinical advances in the treatment strategies available for MM and provides an overview of the state of the art management of patients with MM...
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo cultureM Engelhardt
James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Res 60:610-7. 2000..Telomere shortening during ex vivo expansion correlated with low levels of TA, particularly in chronic leukemic and MDS progenitors where telomerase was insufficient to protect against telomere bp loss during intense proliferation...
Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantationM Engelhardt
University of Freiburg Medical Center, Division Hematology Oncology, Freiburg, Germany
Ann Hematol 80:201-8. 2001..Taken together, our results demonstrate that intermediate-dose rhG-CSF sufficiently mobilizes > or =4x10(6)/kg x bw CD34+ cells with use of LVA and that especially younger donors display increased CD34+ cell numbers...
Telomere length and hTERT expression in patients with acute myeloid leukemia correlate with karyotypic instabilityMonika Engelhardt
Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
Haematologica 90:289B. 2005
Telomeres and telomerase in normal and leukemic hematopoietic cellsMonika Engelhardt
Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
Leuk Res 28:1001-4. 2004..Their results underline the importance to study telomere biology together with cytogenetics, genomic and proteomic profiling as prognostic factors, in order to improve risk-adapted therapy of MDS and AML pts...
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisalMartina Kleber
Department of Hematology and Oncology, Freiburg University Medical Center, Hugstetterstrasse 55, Freiburg, Germany
Clin Lymphoma Myeloma Leuk 12:38-48. 2012..Renal impairment (RI) is a dreaded complication in multiple myeloma (MM) and has been associated with decreased progression-free survival (PFS) and overall survival (OS)...
Does colorectal cancer in ulcerative colitis patients constitute a risk for chemotherapy refractoriness?:a systemic approach by detailed analysis via the electronic tumor base documentation systemMonika Engelhardt
Department of Hematology and Oncology, Clinical Trials Unit, University Medical Center Freiburg, Germany
Onkologie 34:688-94. 2011..Ulcerative colitis (UC) patients may develop colorectal cancer (CRC), especially with pancolitis and longer UC duration. The question whether CRC with underlying UC has a dismal prognosis remains unsettled...
Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapyMartina Kleber
Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
Leuk Lymphoma 53:1057-61. 2012....
Early and mature endothelial progenitors and VEGFR2+-cells in multiple myeloma: association with disease characteristics and variation in different cell compartmentsJosefina Udi
Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
Leuk Res 35:1265-8. 2011..Endothelial cells differed in BM-, PB- and LP-specimens, albeit seemed less associated with unfavorable prognostic MM-parameters. Our data suggest that especially VEGFR2(+)-cells and mature EPCs in MM are of value to explore further...
Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and toleranceJulia Horn
Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
Ann Hematol 91:1579-86. 2012..6--n.r.), respectively. We conclude that R-B is a feasible and safe therapy option in a-B-NHL patients not qualifying for R-CHOP but needs to be further assessed in larger subsequent trials, these currently being under way...
Monitoring bortezomib therapy in multiple myeloma: screening of cyclin D1, D2, and D3 via reliable real-time polymerase chain reaction and association with clinico-pathological features and outcomeBa Thanh Truc Ngo
Department of Hematology and Oncology, University Medical Center, Freiburg, Germany
Leuk Lymphoma 51:1632-42. 2010..0011). Our study is the first to suggest that overexpressed CCND1 in MM is an independent prognostic marker associated with a more durable response to bortezomib. These preliminary results warrant a larger study...
Superiority of magnetic resonance imaging over conventional radiographs in multiple myelomaMonika Engelhardt
Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetterstr 55, 79106 Freiburg, Germany
Anticancer Res 29:4745-50. 2009..The time course of information and linked decision-making point towards the future significance of an intensified integration of imaging methodologies in the classification and disease management of MM...
Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)Michael Lubbert
Department of Hematology Oncology, University of Freiburg, Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Leuk Res 28:1267-71. 2004..In conclusion, restoration of nonclonal hematopoiesis may be the predominant effect of DAC both in early and late stages of treatment, at least in patients achieving a hematologic and cytogenetic response...
Side-population cells from different precursor compartmentsYalin Guo
University of Freiburg Medical Center, Department of Hematology/Oncology, D-79106 Freiburg, Germany
J Hematother Stem Cell Res 12:71-82. 2003..We conclude that human primitive hematopoietic cells can be isolated via Hoechst staining and that SP cells of various human sources show substantial differences and represent a rare CD34(-) population with stem cell potential...
Monitoring APC/C activity in the presence of chromosomal misalignment in unperturbed cell populationsDominik Schnerch
Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany
Cell Cycle 11:310-21. 2012..Since chromosomal misalignment is a rare event, the ability to study entire cell populations enabled us to monitor for the first time SAC surveillance in living cells without the need of highly artificial perturbation by spindle poisons...
CD34- hematopoietic stem cells: current concepts and controversiesYalin Guo
Department of Hematology/Oncology, University of Freiburg Medical Center, Freiburg, Germany
Stem Cells 21:15-20. 2003..In this review, current concepts on murine and human CD34(-) HSCs and their relationship with CD34(+) HSCs are discussed...
Association of multiple myeloma with different neoplasms: systematic analysis in consecutive patients with myelomaJens Hasskarl
Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
Leuk Lymphoma 52:247-59. 2011..Age ≥60 years was a confounding covariable with a HR of 2.021 (95% CI 1.6-2.6)...
Telomere maintenance in human B lymphocytesUwe M Martens
Freiburg University Medical Centre, Department of Haematology Oncology, Germany
Br J Haematol 119:810-8. 2002..Our observations support the concept that telomere dynamics in B cells are distinct from other haematopoietic cell lineages and that telomere elongation may play an essential role in the generation of long-term B memory cells...
Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal surveyNadir Ghanem
Department of Diagnostic Radiology, University Hospital Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
Eur Radiol 16:1005-14. 2006..Therefore, whole-body MRI should be performed as an additional method of exactly staging PCN patients and - with more data in the field - may even prove to be an alternate and more sensitive staging procedure than RSS in PCN patients...
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myelomaMonika Engelhardt
Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
Leuk Lymphoma 51:2006-11. 2010..v. route, is now entering clinical practice. Supportive care remains a crucial aspect in the management of MM. The European Myeloma Network Trialist Group aims to address these contemporary aspects in MM...
Characterization of in vitro growth of multiple myeloma cellsMihaela Zlei
Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
Exp Hematol 35:1550-61. 2007..To develop an in vitro culture system for rapid assessment of multiple myeloma (MM) cell growth...
Management of multiple myeloma in pregnancy: strategies for a rare challengeBenjamin Kasenda
Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
Clin Lymphoma Myeloma Leuk 11:190-7. 2011..Intensified postpartum anti-myeloma therapy should be induced as soon as possible to efficiently reduce myeloma burden and avoid organ damage in these young females...
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patientsMartina Kleber
Department of Hematology and Oncology, Medical Center, University of Freiburg Medical Center, Germany
Eur J Haematol 83:519-27. 2009..Renal impairment (RI) is postulated as one negative prognostic factor in multiple myeloma (MM). The study aim was to detect the best way to define RI and the impact of different RI stages on MM outcome...
Use of systemic antifungals in daily clinical practice in the haematology and oncology setting: results of a prospective observational analysisBarbara Metzke
Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetter Str 55, D 79106 Freiburg, Germany
Pharmacoepidemiol Drug Saf 21:953-63. 2012..To assess the role of systemic antifungal drugs as well as the frequency of potential drug interactions and adverse drug events of commonly used antifungals in an unselected haematology/oncology patient cohort...
Marrow versus blood-derived stem cell grafts for allogeneic transplantation from unrelated donors in patients with active myeloid leukemia or myelodysplasiaHartmut Bertz
Department of Hematology and Oncology, Albert Ludwigs University Medical Center Freiburg, Hugstetter Strasse 55, Freiburg, Germany
Biol Blood Marrow Transplant 18:894-902. 2012..PBSC as a graft source has a significant favorable influence on survival...
Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7Claudia I Muller
Department of Haematology Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
Eur J Haematol 69:115-9. 2002..J. Haematol. 2001: 66: 66-69). Our report of an MDS with trilineage dysplasia and these karyotypic changes associated with DI indicates that this new entity may also include preleukemic cases...
State of the art therapy in multiple myeloma and future perspectivesUlrich Denz
Hematology and Oncology Department, University of Freiburg Medical Center, Hugstetter Strasse 55, 79106 Freiburg, Germany
Eur J Cancer 42:1591-600. 2006..These strategies are incrementally integrated into modern MM care. This review considers recent clinical advancements in anti-myeloma strategies and provides an overview of the state of the art management of MM patients...
Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatmentAnna Markert
Department of Hematology and Oncology, University Medical Center Freiburg, Freiburg, Germany
Int J Cancer 124:722-8. 2009..9%, we recommend our efficient surveillance system as an important safety check, thereby ensuring that chemotherapies are delivered error-free to cancer patients...
Incidence of monoclonal B-cell disease in siblings of patients with multiple myelomaMonika Engelhardt
Haematologica 91:274-6. 2006..From an analysis of five MM families scheduled for allogeneic SCT, monoclonal B-cell disease was detected in 8/27 siblings...
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myelomaMartin Kropff
Department of Medicine Haematology and Oncology, University of Muenster, Muenster, Germany
Br J Haematol 138:330-7. 2007..Bortezomib combined with DEX and CY is a highly effective treatment for relapsed MM at an acceptable rate of grade 3/4 AE. Antiviral prophylaxis appears to be mandatory...
Primary (AL) amyloidosis in plasma cell disordersAntonia M S Müller
Department of Hematology Oncology, University Medical Center Freiburg, Hugstetterstr 55, D 79106 Freiburg, Germany
Oncologist 11:824-30. 2006..This may facilitate earlier diagnosis, and thus allow initiation of prompt and specific therapies, which are indispensable in order to improve disease prognosis...
160 years of multiple myeloma: progress and challengesMonika Engelhardt
Eur J Cancer 42:1507-9. 2006
Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with PegfilgrastimAndreas Jakob
Ann Hematol 84:694-5. 2005
Occurrence of multiple myeloma 13 years after Hodgkin's disease: chance or consequence?Eva Susanne Strobel
Ann Hematol 84:830-2. 2005
